SRZN

Surrozen Inc

31.65

Nov 04 • 3:59 PM ET +1.53 (5.08%)

31.65

Aftermarket • 4:15 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: EYPT KOD OCUL FDMT OTLK RGNX ANNX AURA AGMB BLTE

| Held by: VTI IWM JSMD VXF IWO VTWO IWC GSSC VTWG RSSL

Scroll to Statements

Index	RUT
Market Cap	372.00M
Enterprise Value	276.28M
Income	-350.27M
Sales	11.51M
Book/sh	-18.60
Cash/sh	8.68
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	44
IPO	Jan 11, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	32.32
P/B	-
P/C	3.65
P/FCF	-
EV/EBITDA	-
EV/Sales	24.00
Quick Ratio	12.14
Current Ratio	12.14
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-44.28
EPS next Y	-3.61
EPS next Q	-1.10
EPS this Y	78.33%
EPS next Y	48.52%
EPS next 5Y	51.70%
EPS past 3/5Y	-27.67% 4.68%
Sales past 3/5Y	-34.72% -
EPS Y/Y TTM	-195.46%
Sales Y/Y TTM	-8.79%
EPS Q/Q	-115.90%
Sales Q/Q	408.65%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	68.17% 969.98%

Insider Own	48.17%
Insider Trans	-5.56%
Inst Own	72.11%
Inst Trans	7.08%
ROA	-320.90%
ROE	-
ROIC	-
Gross Margin	98.08%
Oper. Margin	-385.28%
Profit Margin	-3042.91%
SMA20	17.19%
SMA50	28.15%
SMA200	25.28%
Trades

Shs Outstand	11.75M
Shs Float	6.09M
Short Float	51.42%
Short Ratio	5.79
Short Interest	3.13M
52W High	37.83 -16.34%
52W Low	11.39 177.88%
Volatility	6.63% 10.19%
ATR (14)	2.47
RSI (14)	64.20
Beta	0.55
Rel Volume	0.43
Avg Volume	540.51K
Volume	231,065

Perf Week	4.28%
Perf Month	20.02%
Perf Quarter	46.26%
Perf Half Y	-7.27%
Perf YTD	40.04%
Perf Year	151.39%
Perf 3Y	391.84%
Perf 5Y	-73.12%
Perf 10Y	-
Recom	1.00
Target Price	48.40
Prev Close	30.12
Price	31.65
Change %	5.08%

Consensus

Strong Buy

Avg. Price Target

$48.40

Implied Upside

+52.9%

Analysts7incl. previous ratings

Rating Distribution7 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Aug 20, 2026	Initiated	WWilliam Blair	Outperform	$51	+61.1%
Apr 21, 2026	Initiated	TTD Cowen	Buy
Feb 19, 2026	Initiated	CCantor Fitzgerald	Overweight	$40	+26.4%
Jan 30, 2025	Initiated	HH.C. Wainwright	Buy	$32	+1.1%
Jan 03, 2025	Upgrade	GGuggenheim	Neutral → Buy	$45	+42.2%
Oct 11, 2021	Initiated	BBofA Securities	Buy	$11	-65.2%
Sep 15, 2021	Initiated	GGuggenheim	Buy	$20	-36.8%
Sep 07, 2021	Initiated	SStifel	Buy	$19	-40.0%

Oct-20-26 04:59PM	Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million (GlobeNewswire) +5.45%
Oct-15-26 02:22PM	Top Biotech Stock: Guggenheim Names Surrozen as Best Pick (Investing.com) +5.56%
Oct-05-26 06:51AM	Surrozen secures FDA clearance for SZN-8141 clinical trial (Clinical Trials Arena)
Oct-02-26 08:00AM	Surrozen Announces FDA Clearance of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema (GlobeNewswire)
Sep-08-26 08:30AM	Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema (GlobeNewswire) -9.14%
04:05PM	Loading…
Sep-02-26 04:05PM	Surrozen to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire)
Aug-06-26 04:05PM	Surrozen Reports Second Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) +18.39%
Jul-15-26 04:05PM	Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire)
May-12-26 04:05PM	Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire)
May-06-26 04:05PM	Surrozen Reports First Quarter 2026 Financial Results and Provides Business Update (GlobeNewswire) -9.90%
Apr-28-26 04:05PM	Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-14-26 08:21PM	Surrozen (SRZN) Surges 5.9%: Is This an Indication of Further Gains? (Quartz) +6.66%
Mar-23-26 04:05PM	Surrozen Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Feb-25-26 04:05PM	Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire)
Feb-23-26 04:30PM	Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
09:10AM	Loading…
Feb-15-26 09:10AM	Surrozen Conference: CEO Details Wnt-Fzd4 Eye Disease Bet, 2026 IND Plans for SZN-8141 (MarketBeat)
Feb-05-26 04:05PM	Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire) -10.15% +7.29%
Nov-25-25 04:05PM	Surrozen to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) +22.21%
Nov-12-25 05:01PM	Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.80% -6.34%
Nov-07-25 04:05PM	Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-05-25 04:05PM	Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire)
Sep-04-25 04:15PM	Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-03-25 04:15PM	Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire)
Aug-28-25 04:15PM	Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire)
Aug-08-25 04:05PM	Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +5.87%
Aug-06-25 04:30PM	Surrozen to Present at Upcoming Healthcare Investor Conference (GlobeNewswire) -12.83%
May-16-25 09:35AM	Down -29.72% in 4 Weeks, Here's Why Surrozen (SRZN) Looks Ripe for a Turnaround (Zacks)
May-14-25 08:30AM	Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway (GlobeNewswire) -9.72%
May-09-25 04:05PM	Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-31-25 04:05PM	Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates (GlobeNewswire) +5.90%
09:00AM	Loading…
Mar-24-25 09:00AM	Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases (GlobeNewswire)
Nov-06-24 04:30PM	Surrozen to Present at Upcoming Healthcare Investor Conferences (GlobeNewswire) -5.12%
09:00AM	Surrozen Provides Third Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Nov-04-24 08:30AM	Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF- Antibodies for Idiopathic Pulmonary Fibrosis (GlobeNewswire) -10.20%
Sep-24-24 08:30AM	Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration (GlobeNewswire) +8.70%
Aug-12-24 04:05PM	Surrozen Provides Second Quarter 2024 Financial Results and Business Update (GlobeNewswire) -10.14%
Jun-12-24 08:30AM	Surrozen Publishes Study in 'eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling (GlobeNewswire)
Jun-10-24 08:30AM	Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan (GlobeNewswire)
Jun-04-24 08:30AM	Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis (GlobeNewswire)
May-09-24 08:30AM	Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
May-08-24 11:55PM	SRZN Stock Earnings: Surrozen Beats EPS for Q1 2024 (InvestorPlace)
04:05PM	Surrozen Provides First Quarter 2024 Financial Results and Business Update (GlobeNewswire)
Apr-14-24 12:52PM	10 Buy-Rated Stocks with Latest Insider Purchases (Insider Monkey)
Apr-03-24 08:40AM	Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis (GlobeNewswire) +13.41%
Apr-01-24 08:30AM	Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -35.71%
08:30AM	Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043 (GlobeNewswire)
Jan-18-24 09:58AM	Surrozen stops IBD program due to dose concerns and competition (FierceBiotech.com) -5.53%
08:30AM	Surrozen Provides Corporate Update on Clinical Programs (GlobeNewswire)
Dec-14-23 05:52AM	SRZN Stock Earnings: Surrozen Misses EPS for Q1 2023 (InvestorPlace) +9.33%
05:51AM	SRZN Stock Earnings: Surrozen Beats EPS for Q2 2023 (InvestorPlace)
Nov-08-23 04:05PM	Surrozen Provides Third Quarter 2023 Financial Results (GlobeNewswire) -21.17%
Aug-09-23 04:05PM	Surrozen Provides Second Quarter 2023 Financial Results (GlobeNewswire) +5.52% -32.19%
Jun-05-23 08:30AM	Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke (GlobeNewswire)
May-10-23 04:05PM	Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates (GlobeNewswire) -9.43%
Apr-05-23 08:30AM	Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt (GlobeNewswire)
Mar-28-23 04:59AM	Surrozen, Inc. (NASDAQ:SRZN) Q4 2022 Earnings Call Transcript (Insider Monkey) -8.52%
Mar-22-23 04:01PM	Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress (GlobeNewswire) -22.52%
Mar-20-23 04:30PM	Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023 (GlobeNewswire) +21.18%
Jan-04-23 04:41PM	Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-14-22 04:30PM	Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire) -30.17%
Oct-10-22 08:00AM	Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week (GlobeNewswire)
Oct-06-22 08:00AM	Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases (GlobeNewswire)
Sep-26-22 08:00AM	Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy (GlobeNewswire)
Aug-11-22 08:00AM	Surrozen Reports Second Quarter 2022 Financial Results (GlobeNewswire)
Jun-27-22 10:34AM	What Is The Ownership Structure Like For Surrozen, Inc. (NASDAQ:SRZN)? (Simply Wall St.)
Jun-13-22 08:00AM	Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis (GlobeNewswire)
May-24-22 08:00AM	Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW) (GlobeNewswire) -5.75%
May-18-22 08:00AM	Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis (GlobeNewswire) +7.29%
May-16-22 08:00AM	Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD) (GlobeNewswire)
May-11-22 08:00AM	Surrozen Reports First Quarter 2022 Financial Results (GlobeNewswire) -8.74%
May-05-22 08:00AM	Surrozen to Present at the BofA Securities 2022 Healthcare Conference (GlobeNewswire) -12.88%
May-02-22 08:00AM	Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting (GlobeNewswire)
Mar-24-22 08:00AM	Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire) -6.03%
Jan-20-22 09:00AM	Heartland Express, Inc. Reports Fourth Quarter and Annual Financial Results which includes All-Time Record High Annual Earnings Per Share (GlobeNewswire) -7.62%
Jan-10-22 08:00AM	Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline (GlobeNewswire)
Jan-05-22 08:00AM	Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-21 04:00PM	Surrozen Reports Third Quarter 2021 Financial Results (GlobeNewswire)
08:00AM	Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference (GlobeNewswire)
08:00AM	Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases (GlobeNewswire)
Nov-11-21 10:51AM	How Many Surrozen, Inc. (NASDAQ:SRZN) Shares Do Institutions Own? (Simply Wall St.) +19.50%
Nov-05-21 08:00AM	Surrozen to Present at The Stifel 2021 Virtual Healthcare Conference (GlobeNewswire)
Oct-05-21 04:30PM	Surrozen Presented Data Supporting Potential of SZN-1326 at the 2021 United European Gastroenterology Week (GlobeNewswire) -5.75%
Sep-23-21 08:30AM	Surrozen Announces Appointment of Liz Nguyen as Vice President and Head of Human Resources (GlobeNewswire) -9.07%
Aug-11-21 05:30PM	Surrozen Debuts as Publicly Traded Leader in Wnt Biology and Tissue Regeneration (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
TCG Crossover GP II, LLC	10% Owner	Jul 22 '26	Sale	21.25	325,000	6,906,250	574,047	Jul 24 09:00 PM
Li Yang	Exec. Vice President, Research	May 04 '26	Sale	33.33	1,584	52,799	17,216	May 05 04:58 PM
Williams Charles O	Chief Operating Officer	May 04 '26	Sale	33.33	2,036	67,866	16,571	May 05 04:54 PM
Parker Craig C	Chief Executive Officer	May 04 '26	Sale	33.33	4,524	150,798	16,553	May 05 04:51 PM
TCG Crossover GP II, LLC	10% Owner	Mar 24 '26	Buy	24.69	106,658	2,633,717	736,554	Mar 25 08:02 PM
TCG Crossover GP II, LLC	10% Owner	Mar 23 '26	Buy	24.90	15,223	379,051	683,225	Mar 25 08:02 PM
TCG Crossover GP II, LLC	10% Owner	Mar 13 '26	Buy	24.88	35,433	881,463	675,018	Mar 16 07:05 PM
TCG Crossover GP II, LLC	10% Owner	Mar 12 '26	Buy	24.99	12,374	309,166	657,301	Mar 16 07:05 PM
TCG Crossover GP II, LLC	10% Owner	Mar 16 '26	Buy	24.99	1,190	29,733	675,613	Mar 16 07:05 PM
TCG Crossover GP II, LLC	10% Owner	Feb 11 '26	Buy	23.57	17,763	418,763	650,567	Feb 13 04:19 PM
TCG Crossover GP II, LLC	10% Owner	Feb 12 '26	Buy	23.86	1,093	26,082	651,114	Feb 13 04:19 PM
TCG Crossover GP II, LLC	10% Owner	Feb 03 '26	Buy	21.94	4,355	95,549	641,685	Feb 03 08:03 PM
TCG Crossover GP II, LLC	10% Owner	Jan 30 '26	Buy	21.39	4,271	91,357	639,141	Feb 03 08:03 PM
TCG Crossover GP II, LLC	10% Owner	Feb 02 '26	Buy	21.38	731	15,629	639,507	Feb 03 08:03 PM
COLUMN GROUP III GP, LP	10% Owner	Jan 20 '26	Buy	19.60	18,052	353,817	1,016,658	Jan 20 07:35 PM
COLUMN GROUP III GP, LP	10% Owner	Jan 15 '26	Buy	19.89	11,893	236,540	1,005,732	Jan 20 07:35 PM
COLUMN GROUP III GP, LP	10% Owner	Jan 16 '26	Buy	20.00	2,562	51,240	1,007,090	Jan 20 07:35 PM
Kutzkey Tim	Director	Jan 20 '26	Buy	19.60	18,052	353,817	1,016,658	Jan 20 07:31 PM
Kutzkey Tim	Director	Jan 15 '26	Buy	19.89	11,893	236,540	1,005,732	Jan 20 07:31 PM
Kutzkey Tim	Director	Jan 16 '26	Buy	20.00	2,562	51,240	1,007,090	Jan 20 07:31 PM
Kutzkey Tim	Director	Jan 13 '26	Buy	19.80	12,470	246,957	996,502	Jan 15 04:11 PM
Kutzkey Tim	Director	Jan 14 '26	Buy	19.99	5,523	110,395	999,429	Jan 15 04:11 PM
COLUMN GROUP III GP, LP	10% Owner	Jan 13 '26	Buy	19.80	12,470	246,957	996,502	Jan 15 04:10 PM
COLUMN GROUP III GP, LP	10% Owner	Jan 14 '26	Buy	19.99	5,523	110,395	999,429	Jan 15 04:10 PM
COLUMN GROUP III GP, LP	10% Owner	Jan 06 '26	Buy	19.89	15,100	300,297	989,893	Jan 08 05:23 PM
Kutzkey Tim	Director	Jan 06 '26	Buy	19.89	15,100	300,297	989,893	Jan 08 05:19 PM
Li Yang	Exec. Vice President, Research	Jan 05 '26	Sale	19.87	1,118	22,209	16,091	Jan 06 08:25 PM
Williams Charles O	Chief Operating Officer	Jan 05 '26	Sale	19.87	1,566	31,109	12,982	Jan 06 08:22 PM
Kutzkey Tim	Director	Dec 05 '25	Buy	19.54	30,884	603,501	981,890	Dec 08 05:09 PM
Kutzkey Tim	Director	Dec 04 '25	Buy	17.35	5,266	91,349	965,509	Dec 08 05:09 PM
COLUMN GROUP III GP, LP	10% Owner	Dec 05 '25	Buy	19.54	30,884	603,501	981,890	Dec 08 05:04 PM
COLUMN GROUP III GP, LP	10% Owner	Dec 04 '25	Buy	17.35	5,266	91,349	965,509	Dec 08 05:04 PM
Kutzkey Tim	Director	Nov 13 '25	Buy	12.65	315,457	3,990,531	962,718	Dec 02 09:36 PM
COLUMN GROUP III GP, LP	10% Owner	Nov 13 '25	Buy	12.65	315,457	3,990,531	962,718	Nov 17 07:15 PM

Surrozen, Inc. is a clinical stage biotechnology company, which engages in the business of discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company was founded by K. Christopher Garcia and Roeland Nusse on August 12, 2015 and is headquartered in South San Francisco, CA.

CEOMr. Craig C. Parker M.B.A.

COO & Corporate SecretaryMr. Charles Williams

Executive Vice President of ResearchDr. Yang Li Ph.D.

Co-Founder & Member of Scientific Advisory BoardDr. K. Christopher Garcia Ph.D.

Co-Founder & Member of Scientific Advisory BoardDr. Roeland Nusse Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SRZN

Surrozen Inc

Upgrade your Finviz experience